WEKO3
アイテム
{"_buckets": {"deposit": "3d84d6cd-c912-4c4f-95d6-10c73fc587c5"}, "_deposit": {"created_by": 6, "id": "26822", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "26822"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00026822", "sets": ["11"]}, "author_link": ["118840", "118835", "118841", "118845", "118839", "118831", "118826", "118828", "118832", "118824", "118827", "118825", "118830", "118842", "118847", "118838", "118836", "118846", "118834", "118833", "118823", "118843", "118844", "118829", "118837"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-06-01", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "art. no. 506", "bibliographicVolumeNumber": "22", "bibliographic_titles": [{"bibliographic_title": "BMC Musculoskeletal Disorders"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept.\nMethods: We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change.\nResults: Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status.\nConclusion: Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept.\nTrial registration: Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study\nTrial registration number: UMIN000012524\nDate of registration: 12/9/2013\nURL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "BMC Musculoskeletal Disorders, 22, art. no. 506; 2021", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "BioMed Central Ltd"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1186/s12891-021-04392-5", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article\u0027s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article\u0027s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14712474", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kawashiri, Shin-ya"}], "nameIdentifiers": [{"nameIdentifier": "118823", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Endo, Yushiro"}], "nameIdentifiers": [{"nameIdentifier": "118824", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishino, Ayako"}], "nameIdentifiers": [{"nameIdentifier": "118825", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okamoto, Momoko"}], "nameIdentifiers": [{"nameIdentifier": "118826", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Sosuke"}], "nameIdentifiers": [{"nameIdentifier": "118827", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takatani, Ayuko"}], "nameIdentifiers": [{"nameIdentifier": "118828", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimizu, Toshimasa"}], "nameIdentifiers": [{"nameIdentifier": "118829", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sumiyoshi, Remi"}], "nameIdentifiers": [{"nameIdentifier": "118830", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Koga, Tomohiro"}], "nameIdentifiers": [{"nameIdentifier": "118831", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iwamoto, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "118832", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichinose, Kunihiro"}], "nameIdentifiers": [{"nameIdentifier": "118833", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tamai, Mami"}], "nameIdentifiers": [{"nameIdentifier": "118834", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "118835", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Origuchi, Tomoki"}], "nameIdentifiers": [{"nameIdentifier": "118836", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aramaki, Toshiyuki"}], "nameIdentifiers": [{"nameIdentifier": "118837", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ueki, Yukitaka"}], "nameIdentifiers": [{"nameIdentifier": "118838", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshitama, Tamami"}], "nameIdentifiers": [{"nameIdentifier": "118839", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Eiraku, Nobutaka"}], "nameIdentifiers": [{"nameIdentifier": "118840", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuoka, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "118841", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okada, Akitomo"}], "nameIdentifiers": [{"nameIdentifier": "118842", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujikawa, Keita"}], "nameIdentifiers": [{"nameIdentifier": "118843", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hamada, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "118844", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagano, Shuji"}], "nameIdentifiers": [{"nameIdentifier": "118845", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tada, Yoshifumi"}], "nameIdentifiers": [{"nameIdentifier": "118846", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawakami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "118847", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-10-28"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "BMCMD22_506.pdf", "filesize": [{"value": "793.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 793300.0, "url": {"label": "BMCMD22_506.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/26822/files/BMCMD22_506.pdf"}, "version_id": "a23d7575-83e4-4639-a936-fd7c7a732105"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Rheumatoid arthritis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Musculoskeletal ultrasound", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Abatacept", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Dickkopf-1", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Osteoprotegerin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Power Doppler", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Sclerostin", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan"}]}, "item_type_id": "2", "owner": "6", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/00040991", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-10-28"}, "publish_date": "2021-10-28", "publish_status": "0", "recid": "26822", "relation": {}, "relation_version_is_last": true, "title": ["Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan"], "weko_shared_id": -1}
Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
http://hdl.handle.net/10069/00040991
http://hdl.handle.net/10069/000409912b99ce59-86a4-4a3e-8ae9-517b3ce5a464
名前 / ファイル | ライセンス | アクション |
---|---|---|
BMCMD22_506.pdf (793.3 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-10-28 | |||||
タイトル | ||||||
タイトル | Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Rheumatoid arthritis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Musculoskeletal ultrasound | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Abatacept | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Dickkopf-1 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Osteoprotegerin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Power Doppler | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Sclerostin | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kawashiri, Shin-ya
× Kawashiri, Shin-ya× Endo, Yushiro× Nishino, Ayako× Okamoto, Momoko× Tsuji, Sosuke× Takatani, Ayuko× Shimizu, Toshimasa× Sumiyoshi, Remi× Koga, Tomohiro× Iwamoto, Naoki× Ichinose, Kunihiro× Tamai, Mami× Nakamura, Hideki× Origuchi, Tomoki× Aramaki, Toshiyuki× Ueki, Yukitaka× Yoshitama, Tamami× Eiraku, Nobutaka× Matsuoka, Naoki× Okada, Akitomo× Fujikawa, Keita× Hamada, Hiroaki× Nagano, Shuji× Tada, Yoshifumi× Kawakami, Atsushi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. Methods: We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. Results: Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status. Conclusion: Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept. Trial registration: Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657 |
|||||
書誌情報 |
BMC Musculoskeletal Disorders 巻 22, p. art. no. 506, 発行日 2021-06-01 |
|||||
出版者 | ||||||
出版者 | BioMed Central Ltd | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14712474 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1186/s12891-021-04392-5 | |||||
権利 | ||||||
権利情報 | © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | BMC Musculoskeletal Disorders, 22, art. no. 506; 2021 |